Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options

Rhea-AI Filing Summary

ARS Pharmaceuticals director Rajeev Dadoo received a new stock option grant. He was awarded options covering 30,000 shares of common stock at an exercise price of $10.54 per share, expiring on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dadoo Rajeev

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 30,000 options Exercise price: $10.54 per share Underlying shares: 30,000 shares +2 more

5 metrics

Option grant size 30,000 options Stock Option (right to buy) granted on June 24, 2026

Exercise price $10.54 per share Conversion or exercise price for the stock options

Underlying shares 30,000 shares Common Stock underlying the option grant

Post-grant derivative holdings 30,000 options Total derivative securities following the transaction

Option expiration June 23, 2036 Expiration date of the stock options

Key Terms

Stock Option (right to buy), exercise price, expiration date, vesting

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.5400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 04:21 PM Accepted by SEC EDGAR 06/26/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dadoo Rajeev

(Last) (First) (Middle)

929 MAIN STREET

SUITE 200

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.54	06/24/2026		A		30,000		(1)	06/23/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

	/s/ Sasha Keough, attorney-in-fact for Rajeev Dadoo	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ARS Pharmaceuticals (SPRY) report for Rajeev Dadoo?

ARS Pharmaceuticals reported that director Rajeev Dadoo received a stock option grant for 30,000 shares. The options are a compensation-related award, not an open-market share purchase or sale.

How many ARS Pharmaceuticals (SPRY) shares are covered by Rajeev Dadoo’s new options?

The grant covers options on 30,000 shares of ARS Pharmaceuticals common stock. This award increases his derivative-based exposure to the company through stock options rather than immediate ownership of common shares.

What is the exercise price of Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) stock options?

The stock options have an exercise price of $10.54 per share. This is the price at which he can buy ARS Pharmaceuticals common stock if he chooses to exercise the options in the future.

When do Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) options vest?

The options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting. Vesting must occur before Mr. Dadoo can exercise the options for common shares.

When do Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) stock options expire?

The stock options expire on June 23, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase ARS Pharmaceuticals common stock.

Is Rajeev Dadoo’s ARS Pharmaceuticals (SPRY) Form 4 a buy or sell signal?

The Form 4 reflects a compensation-related stock option grant, not a market trade. It is classified as an acquisition of derivative securities through an award rather than an open-market buy or sell transaction.